Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

Nicorette (nicotine polacrilex)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved February 1996

Specific Treatments:

smoking cessation

Therapeutic Areas

General Information

Nicorette has been approved as an over-the-counter (OTC) aid in smoking cessation. The OTC nicotine gum product will be available in the same dosage strengths as the prescription product.

Nicorette relieves withdrawal symptoms by providing a temporary alternative source of nicotine, thereby easing the transition for an individual committed to smoking cessation. The nicotine in Nicorette reaches the bloodstream more gradually and at lower doses than delivered by cigarettes. While Nicorette controls withdrawal symptoms, thus addressing the physical addiction of smoking, the individual works to control the social and psychological aspects of the smoking habit.

The OTC version of Nicorette will be available in prescription strengths of 2 mg and 4 mg.

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation